Literature DB >> 26928832

Refractory and/or Relapsing Cryptococcosis Associated with Acquired Immune Deficiency Syndrome: Clinical Features, Genotype, and Virulence Factors of Cryptococcus spp. Isolates.

Erika Nascimento1, Lucia H Vitali2, Ludmilla Tonani2, Marcia R Von Zeska Kress2, Osvaldo M Takayanagui2, Roberto Martinez2.   

Abstract

Refractory and relapsing crytocococcosis in acquired immune deficiency syndrome (AIDS) patients have a poor prognosis. The risk factors for this complicated infection course were evaluated by comparing refractory and/or relapsing cryptococcosis in human immunodeficiency virus-coinfected patients (cohort 1) with another group of AIDS patients who adequately responded to antifungals (cohort 2). Except for one isolate of Cryptococcus gattii from a cohort 2 case, all other isolates were identified as Cryptococcus neoformans var. grubii, sex type α, genotype VNI, including Cryptococcus reisolated from the relapse or in the refractory state. No differences were observed with respect to Cryptococcus capsule size and in the melanin and phospholipase production. The cohort 1 patients presented higher prevalence of cryptococcemia, cerebral dissemination, chronic liver disease, and leucopenia, and have increased death rate. Apparently, the refractory and/or relapsing cryptococcosis in the AIDS patients were more related to the host and the extent of the infection than to the fungal characteristics. © The American Society of Tropical Medicine and Hygiene.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26928832      PMCID: PMC4856629          DOI: 10.4269/ajtmh.15-0595

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  36 in total

1.  Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings.

Authors:  S Antinori; L Galimberti; C Magni; A Casella; L Vago; F Mainini; M Piazza; M Nebuloni; M Fasan; C Bonaccorso; G M Vigevani; A Cargnel; M Moroni; A Ridolfo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2001-10       Impact factor: 3.267

2.  Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex.

Authors:  Luciana Trilles; Wieland Meyer; Bodo Wanke; Josep Guarro; Marcia Lazéra
Journal:  Med Mycol       Date:  2011-08-23       Impact factor: 4.076

Review 3.  Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.

Authors:  Benjamin J Park; Kathleen A Wannemuehler; Barbara J Marston; Nelesh Govender; Peter G Pappas; Tom M Chiller
Journal:  AIDS       Date:  2009-02-20       Impact factor: 4.177

4.  Approaches to antifungal therapies and their effectiveness among patients with cryptococcosis.

Authors:  Emily W Bratton; Nada El Husseini; Cody A Chastain; Michael S Lee; Charles Poole; Til Stürmer; David J Weber; Jonathan J Juliano; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

5.  Clinical and epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil.

Authors:  Andrea de Siqueira Campos Lindenberg; Marilene Rodrigues Chang; Anamaria Melo Miranda Paniago; Márcia dos Santos Lazéra; Paula Maria Frank Moncada; Gisele Facholi Bonfim; Susie Andries Nogueira; Bodo Wanke
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2008 Mar-Apr       Impact factor: 1.846

6.  Investigation of the basis of virulence in serotype A strains of Cryptococcus neoformans from apparently immunocompetent individuals.

Authors:  Cletus A D'Souza; Ferry Hagen; Teun Boekhout; Gary M Cox; Joseph Heitman
Journal:  Curr Genet       Date:  2004-05-19       Impact factor: 3.886

7.  Dynamics of Cryptococcus neoformans-macrophage interactions reveal that fungal background influences outcome during cryptococcal meningoencephalitis in humans.

Authors:  Alexandre Alanio; Marie Desnos-Ollivier; Françoise Dromer
Journal:  MBio       Date:  2011-08-09       Impact factor: 7.867

8.  Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients.

Authors:  Tihana Bicanic; Conrad Muzoora; Annemarie E Brouwer; Graeme Meintjes; Nicky Longley; Kabanda Taseera; Kevin Rebe; Angela Loyse; Joseph Jarvis; Linda-Gail Bekker; Robin Wood; Direk Limmathurotsakul; Wirongrong Chierakul; Kasia Stepniewska; Nicholas J White; Shabbar Jaffar; Thomas S Harrison
Journal:  Clin Infect Dis       Date:  2009-09-01       Impact factor: 9.079

9.  Microbiological, epidemiological, and clinical characteristics and outcomes of patients with cryptococcosis in Taiwan, 1997-2010.

Authors:  Hsiang-Kuang Tseng; Chang-Pan Liu; Mao-Wang Ho; Po-Liang Lu; Hsiu-Jung Lo; Yu-Hui Lin; Wen-Long Cho; Yee-Chun Chen
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

10.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  3 in total

1.  Fluconazole Non-susceptible Cryptococcus neoformans, Relapsing/Refractory Cryptococcosis and Long-term Use of Liposomal Amphotericin B in an AIDS Patient.

Authors:  Rodrigo de Carvalho Santana; Letícia Aparecida Schiave; Alda Soares Dos Santos Quaglio; Cristiane Masetto de Gaitani; Roberto Martinez
Journal:  Mycopathologia       Date:  2017-06-27       Impact factor: 2.574

2.  Cryptococcus neoformans and C. gattii isolates from both HIV-infected and uninfected patients: antifungal susceptibility and outcome of cryptococcal disease.

Authors:  Erika Nascimento; Lucia Helena Vitali; Marcia Regina von Zeska Kress; Roberto Martinez
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-08-03       Impact factor: 1.846

3.  Fluconazole levels in serum and cerebrospinal fluid according to daily dosage in patients with cryptococcosis and other fungal infections.

Authors:  Letícia Aparecida Schiave; Erika Nascimento; Fernando Crivelenti Vilar; Tissiana Marques de Haes; Osvaldo Massaiti Takayanagui; Cristiane Masetto de Gaitani; Roberto Martinez
Journal:  Braz J Infect Dis       Date:  2017-11-13       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.